LENZ Therapeutics Inc (LENZ)
Healthcare
Biotechnology
5.30 $
-8.0%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns LENZ Therapeutics Inc (LENZ)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 58.9% of the shares are freely tradable; institutional investors hold 107.6%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
107.6%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
2.7%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
58.9%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
54.5%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
31Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| RA Capital Management, LLC | 13.33 | 4,178,823 | +0.0 | 03/31/2026 |
| Alpha Wave Global LP | 11.52 | 3,612,211 | +0.0 | 03/31/2026 |
| FMR Inc | 11.47 | 3,597,784 | -2.8 | 03/31/2026 |
| Versant Venture Management LLC | 8.47 | 2,656,888 | +0.0 | 03/31/2026 |
| BlackRock Inc | 6.30 | 1,976,823 | +16.8 | 03/31/2026 |
| Squarepoint Ops LLC | 4.80 | 1,506,499 | +206.3 | 03/31/2026 |
| Vanguard Group Inc | 4.21 | 1,321,202 | -0.7 | 12/31/2025 |
| Aberdeen Group PLC | 3.69 | 1,156,161 | +136.2 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity Growth Compy Commingled Pl S | 5.26 | 1,650,287 | +0.1 | 04/30/2026 |
| Fidelity Growth Company Fund | 3.92 | 1,228,633 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.